Research ArticleDrug Discovery and Translational Medicine
A Novel In Vivo Receptor Occupancy Methodology for the Glucocorticoid Receptor: Toward An Improved Understanding of Lung Pharmacokinetic/Pharmacodynamic Relationships
Elin Boger, Pär Ewing, Ulf G. Eriksson, Britt-Marie Fihn, Michael Chappell, Neil Evans and Markus Fridén
Journal of Pharmacology and Experimental Therapeutics May 2015, 353 (2) 279-287; DOI: https://doi.org/10.1124/jpet.114.221226
Elin Boger
Respiratory, Inflammation and Autoimmunity innovative Medicines, AstraZeneca R&D, Mölndal, Sweden (E.B., P.E., U.G.E., B.-M.F., M.F.); School of Engineering, University of Warwick, Coventry, United Kingdom (E.B, M.C., N.E.); and Translational PKPD, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden (M.F.)
Pär Ewing
Respiratory, Inflammation and Autoimmunity innovative Medicines, AstraZeneca R&D, Mölndal, Sweden (E.B., P.E., U.G.E., B.-M.F., M.F.); School of Engineering, University of Warwick, Coventry, United Kingdom (E.B, M.C., N.E.); and Translational PKPD, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden (M.F.)
Ulf G. Eriksson
Respiratory, Inflammation and Autoimmunity innovative Medicines, AstraZeneca R&D, Mölndal, Sweden (E.B., P.E., U.G.E., B.-M.F., M.F.); School of Engineering, University of Warwick, Coventry, United Kingdom (E.B, M.C., N.E.); and Translational PKPD, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden (M.F.)
Britt-Marie Fihn
Respiratory, Inflammation and Autoimmunity innovative Medicines, AstraZeneca R&D, Mölndal, Sweden (E.B., P.E., U.G.E., B.-M.F., M.F.); School of Engineering, University of Warwick, Coventry, United Kingdom (E.B, M.C., N.E.); and Translational PKPD, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden (M.F.)
Michael Chappell
Respiratory, Inflammation and Autoimmunity innovative Medicines, AstraZeneca R&D, Mölndal, Sweden (E.B., P.E., U.G.E., B.-M.F., M.F.); School of Engineering, University of Warwick, Coventry, United Kingdom (E.B, M.C., N.E.); and Translational PKPD, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden (M.F.)
Neil Evans
Respiratory, Inflammation and Autoimmunity innovative Medicines, AstraZeneca R&D, Mölndal, Sweden (E.B., P.E., U.G.E., B.-M.F., M.F.); School of Engineering, University of Warwick, Coventry, United Kingdom (E.B, M.C., N.E.); and Translational PKPD, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden (M.F.)
Markus Fridén
Respiratory, Inflammation and Autoimmunity innovative Medicines, AstraZeneca R&D, Mölndal, Sweden (E.B., P.E., U.G.E., B.-M.F., M.F.); School of Engineering, University of Warwick, Coventry, United Kingdom (E.B, M.C., N.E.); and Translational PKPD, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden (M.F.)
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleDrug Discovery and Translational Medicine
Novel In Vivo Glucocorticoid Receptor Occupancy Methodology
Elin Boger, Pär Ewing, Ulf G. Eriksson, Britt-Marie Fihn, Michael Chappell, Neil Evans and Markus Fridén
Journal of Pharmacology and Experimental Therapeutics May 1, 2015, 353 (2) 279-287; DOI: https://doi.org/10.1124/jpet.114.221226
Research ArticleDrug Discovery and Translational Medicine
Novel In Vivo Glucocorticoid Receptor Occupancy Methodology
Elin Boger, Pär Ewing, Ulf G. Eriksson, Britt-Marie Fihn, Michael Chappell, Neil Evans and Markus Fridén
Journal of Pharmacology and Experimental Therapeutics May 1, 2015, 353 (2) 279-287; DOI: https://doi.org/10.1124/jpet.114.221226
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement